人肺树突状细胞:空间分布与表型鉴定支气管活检采用免疫组化和流式细胞仪
2017年1月20日
8.6K 次观看
肺驻留免疫细胞，包括人类的树突状细胞 （DC），对于防御吸入病原体和过敏原至关重要。然而，由于人类肺组织的稀缺性，研究是有限的。这项工作提出了处理人粘膜支气管内活检的方案，以使用免疫组织化学和流式细胞术研究肺 DC。
这种技术的主要优点是可以从支气管镜检查过程中获得的小组织中产生大量信息。这种方法可以帮助回答粘膜免疫学中的关键问题，其中支气管镜检查是确定诊断的一部分，例如 COPD、结节病或肺癌。该程序的视觉演示将使刚接触该方法的人能够识别酶消化何时完成。与 Faezzah Baharom 一起演示此程序的是 Greg Rankin，他是我们在 Ume 的合作者实验室的博士后
查看完整文字稿并访问数千部科学视频
概述
本研究聚焦于肺部驻留的免疫细胞，特别是树突状细胞（DCs），它们在防御吸入的病原体和过敏原方面发挥着至关重要的作用。由于人类肺组织的有限供应，这一领域的研究受到了限制。本文介绍了处理人类黏膜支气管内活检以使用免疫组织化学和流式细胞术研究肺部DCs的协议。
研究的关键组成部分
科学领域
- 免疫学
- 呼吸生物学
- 细胞生物学
背景
- 肺部DCs对呼吸道的免疫反应至关重要。
- 人类肺组织稀缺，限制了研究机会。
- 了解肺部DCs可以提供对呼吸系统疾病的洞察。
- 研究这些细胞的协议对推进研究是必要的。
研究目的
- 开发处理支气管内活检的协议。
- 促进人类组织中肺部DCs的研究。
- 增进对肺部免疫反应的理解。
使用的方法
- 免疫组织化学用于在组织样本中可视化DCs。
- 流式细胞术用于分析细胞群体。
- 处理人类黏膜支气管内活检。
- 标准化的协议以确保可重复性。
主要结果
- 成功处理支气管内活检以进行分析。
- 使用免疫组织化学鉴定肺部DCs。
- 流式细胞术揭示了不同的免疫细胞群体。
- 建立的协议可用于未来的研究。
结论
- 开发的协议使得详细研究肺部DCs成为可能。
- 研究发现可以为理解肺部免疫做出贡献。
- 未来的研究可以在这些方法基础上探索呼吸健康。
常见问题
树突状细胞是什么？
树突状细胞是处理和呈现抗原给T细胞的免疫细胞，在启动免疫反应中发挥着关键作用。
为什么人类肺组织稀缺？
由于伦理考虑和从活体个体获取样本的困难，人类肺组织有限。
免疫组织化学如何工作？
免疫组织化学使用抗体在组织切片中检测特定蛋白质，允许可视化细胞类型及其分布。
什么是流式细胞术？
流式细胞术是一种技术，用于分析细胞或颗粒在流过激光时的物理和化学特性。
研究肺部DCs的意义是什么？
研究肺部DCs有助于理解对病原体和过敏原的免疫反应，这对于开发呼吸系统疾病的治疗方法很重要。
这些协议可以应用于其他组织吗？
虽然这些协议是为肺组织设计的，但类似的方法可以调整以用于其他类型的组织。
Executive Industry Relevance
Understanding lung dendritic cell biology is critical for de-risking immunotherapeutic targets in respiratory diseases. This method enables phenotypic and spatial profiling of rare immune cells from minimally invasive biopsies, supporting target validation in early discovery. It provides mechanistic insights into antigen presentation and immune tolerance, informing go/no-go decisions for pulmonary indications.
Strategic Applications in Biopharma R&D
Early Discovery & Target Validation
- Scientific Value: Enables interrogation of dendritic cell phenotypes in human lung tissue to validate therapeutic targets involved in antigen presentation.
- Operational Value: Uses endobronchial biopsies to access disease-relevant immune cells without requiring invasive lung resection.
- Predictive Value: Supports biomarker discovery for patient stratification in immunotherapies targeting lung immunity.
Screening & Assay Development
- Assay Readiness: Generates standardized single-cell suspensions from digested biopsies for reproducible flow cytometric immunophenotyping.
- Quantitative Output: Enables precise measurement of dendritic cell frequency and activation states as pharmacodynamic readouts.
- Scalability: Optimized for small tissue samples, allowing longitudinal monitoring in preclinical and clinical cohorts.
Translational & Preclinical Research
- Disease Relevance: Directly applicable to biopsies from patients with COPD, sarcoidosis, or lung cancer to compare DC alterations in disease states.
- Translational Continuity: Bridges ex vivo human tissue findings with preclinical models to validate mechanistic hypotheses.
- Risk Mitigation: Reduces biological de-risking uncertainty by confirming target engagement in primary human lung immune cells.
Pipeline & Workflow Integration
The method fits within the discovery workflow from target hypothesis validation through preclinical mechanistic studies, enabling iterative refinement of immunomodulatory candidates.
- Discovery Biology: Supports hypothesis testing by mapping dendritic cell spatial distribution and phenotype in response to inhaled antigens or therapeutics.
- Screening: Delivers standardized, quantitative immune profiling data suitable for high-content screening of compound libraries.
- Analytics: Provides multiparametric flow cytometry readouts to quantify co-stimulatory markers, cytokine receptors, and maturation states.
- Translational Research: Enables comparison of DC profiles across healthy and diseased lung tissues to inform biomarker-led patient selection.
- Enterprise Reuse: Establishes a reusable platform for immune monitoring in respiratory drug development programs.
Operational & Enterprise Impact
- Scientific Value: Increases target confidence by validating dendritic cell modulation in primary human lung tissue.
- Operational Value: Delivers reproducible, standardized protocols for immune cell isolation and characterization from bronchoscopy samples.
- Strategic Value: Improves capital efficiency by enabling early detection of off-target immune effects in lung tissue.
- Portfolio Impact: Supports risk-adjusted prioritization of immunomodulators based on human lung dendritic cell activity.
Implementation Considerations
- Requires expertise in immunohistochemistry staining, flow cytometry panel design, and enzymatic tissue dissociation.
- Dependent on access to bronchoscopy-derived biopsies and optimized digestion protocols for low-yield cell recovery.
- Necessitates standardization across sites for multicenter studies to ensure comparability of DC phenotyping data.
- Must account for donor variability and tissue processing time when interpreting dendritic cell frequencies and activation states.
- Limited by the low abundance of dendritic cells in steady-state lung tissue, requiring sensitive detection methods and sufficient sample pooling.
Biopharma FAQs
Why is phenotypic identification of lung dendritic cells important for target validation?
Phenotypic identification confirms the presence and activation state of dendritic cells in human lung tissue, which is essential for validating targets involved in antigen presentation and immune modulation. This ensures that therapeutic candidates engage the intended biological mechanism in a disease-relevant context.
How does spatial distribution analysis using immunohistochemistry support mechanistic de-risking?
Spatial mapping reveals dendritic cell localization within bronchial epithelium and submucosa, indicating their accessibility to inhaled antigens or therapeutics. This helps de-risk mechanisms by showing whether targets are positioned to interact with environmental stimuli or drug delivery sites.
What quantitative dependent variable measurements does flow cytometry enable for dendritic cell assessment?
Flow cytometry enables quantification of dendritic cell frequency, surface marker expression (e.g., HLA-DR, CD11c), and maturation status (e.g., CD80, CD86) as dependent variables. These metrics allow comparison across conditions to assess immunomodulatory effects of test compounds.
Why do replication requirements matter for cross-functional collaboration in lung immunology studies?
Replication ensures that dendritic cell phenotypes and frequencies are consistent across donors and experiments, which is critical for aligning discovery, preclinical, and clinical teams on reliable data. Consistent results build confidence in target validity and support coordinated decision-making.
What statistical analysis capabilities are required before implementing this method in a discovery pipeline?
Implementation requires capability to perform multivariate analysis of flow cytometry data, including gating strategies, statistical comparison of cell populations, and correction for multiple comparisons. This ensures robust interpretation of dendritic cell changes in response to therapeutic interventions.
Chapters in this video
0:05
Title
1:01
Glycol Methylacrylate (GMA) Resin Endobronchial Biopsy Embedment
2:32
GMA-embedded Endobronchial Biopsy Immunohistochemical Staining
5:23
Endobronchial Biopsy Enzymatic Digestion and Flow Cytometric Analysis
8:17
Results: Identifying Immune and Dendritic Cell Subsets in Endobronchial Biopsies
10:08
Conclusion
